Cargando…
Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?
Cancer therapy–related cardiac dysfunction (CTRCD) is one of the most concerning cardiovascular side effects of cancer treatment. Important reviews within the field of cardio-oncology have described various agents to be associated with a high risk of CTRCD, including mitomycin C, ifosfamide, vincris...
Autores principales: | Kamphuis, Janine A.M., Linschoten, Marijke, Cramer, Maarten J., Gort, Eelke H., van Rhenen, Anna, Asselbergs, Folkert W., Doevendans, Pieter A., Teske, Arco J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352330/ https://www.ncbi.nlm.nih.gov/pubmed/34396190 http://dx.doi.org/10.1016/j.jaccao.2019.09.007 |
Ejemplares similares
-
Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy
por: Kamphuis, Janine A. M., et al.
Publicado: (2020) -
LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review
por: Printezi, Markella I., et al.
Publicado: (2022) -
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?
por: Thuny, Franck, et al.
Publicado: (2022) -
Primer on Biomarker Discovery in Cardio-Oncology: Application of Omics Technologies
por: Rhee, June-Wha, et al.
Publicado: (2020) -
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
por: Zhang, Lili, et al.
Publicado: (2021)